GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Cash-to-Debt

Nuvation Bio (Nuvation Bio) Cash-to-Debt : 152.54 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nuvation Bio's cash to debt ratio for the quarter that ended in Dec. 2023 was 152.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nuvation Bio could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Nuvation Bio's Cash-to-Debt or its related term are showing as below:

NUVB' s Cash-to-Debt Range Over the Past 10 Years
Min: 152.54   Med: 202.85   Max: No Debt
Current: 152.54

During the past 4 years, Nuvation Bio's highest Cash to Debt Ratio was No Debt. The lowest was 152.54. And the median was 202.85.

NUVB's Cash-to-Debt is ranked better than
81.29% of 1539 companies
in the Biotechnology industry
Industry Median: 6.54 vs NUVB: 152.54

Nuvation Bio Cash-to-Debt Historical Data

The historical data trend for Nuvation Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nuvation Bio Cash-to-Debt Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
No Debt 250.54 155.17 152.54

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.17 162.83 171.63 138.74 152.54

Competitive Comparison of Nuvation Bio's Cash-to-Debt

For the Biotechnology subindustry, Nuvation Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Cash-to-Debt falls into.



Nuvation Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nuvation Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Nuvation Bio's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvation Bio  (NYSE:NUVB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Nuvation Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Executives
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Venture Opportunity Fund, Lp director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund Qualified, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dongfang Liu officer: Chief Medical Officer C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 401, NEW YORK NY 10036
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
David C. Hanley officer: Chief Technical Operations C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Kim D Blickenstaff director C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105